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Abstract
Acute chorioamnionitis, frequently observed in preterm placentas, is a major risk factor for the development of infection and non-infec-
tion-related adverse perinatal outcomes. MicroRNAs play important roles in immune cell development and function as well as in the devel-
opment of cancers and neurologic diseases. We sought to investigate the changes in microRNA-223 (miR-223) expression and the
functional significance of the changes in miR-223 expression in foetal organs in the presence of acute chorioamnionitis. Using formalin-
fixed, paraffin-embedded (FFPE) tissue samples from foetal or neonatal autopsy cases, which are the most practical option to study the
changes in several organs simultaneously, miR-223 expression profiles in foetal thymus, lung and liver were compared between cases with
and without acute chorioamnionitis. Total RNA was extracted from FFPE specimens and qRT-PCR was conducted. miR-223-3p expression
levels in foetal thymus (2.55-fold), lung (1.93-fold) and liver (1.70-fold) were significantly higher in cases with acute chorioamnionitis than
in those without. Transfection of pre-miR-223-3p in Jurkat cells and luciferase assay and ribonucleoprotein immunoprecipitation followed
by qRT-PCR analysis confirmed the binding of miR-223 to the 30 untranslated region (30UTR) of forkhead box O1 (FoxO1) mRNA and the
regulation of FoxO1 by miR-223. We report for the first time that foetuses with inflammation in the chorioamniotic membranes show
increased expression of miR-223 in the thymus, lung and liver. Furthermore, FoxO1 is a target of miR-223. These findings suggest that
post-transcriptional regulation of genes by miR-223 is a component of the foetal inflammatory response, which has systemic conse-
quences in the foetus.
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Introduction
Acute chorioamnionitis is frequently diagnosed in preterm placen-
tas and is a major risk factor for the development of infection
and non-infection-related perinatal morbidity and mortality [1]. The
presence of acute chorioamnionitis indicates the acute inflamma-
tory responses of mothers and foetuses to bacterial infection in
the gestational sac [2] and is generally considered as a histologic
hallmark for intra-amniotic infection and/or inflammation [3, 4],
given that the elevation of many intra-amniotic inflammatory mark-
ers has been reported to be associated with acute chorioamnioni-
tis [1].
MicroRNAs (miRNAs) are small, single-stranded, non-coding RNA
(usually 18–24 nucleotides) [5] that play an important role in the post-
transcriptional regulation of gene expression. Approximately 2,000
miRNAs have been reported, and about 60% of protein synthesis
genes are thought to be regulated by miRNAs [6–9]. Aberrations of
miRNAs expression are associated with the development of major
human diseases such as cancers and neurologic diseases [10]. As
miRNAs are relatively stable, they have been successfully investigated
using formalin-fixed, paraffin-embedded (FFPE) tissue samples [11–
16]. In the obstetric fields, however, the number of studies on miRNAs
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in placental tissues, trophoblasts and maternal blood samples is limited
in cases with congenital anomalies and perinatal diseases [17–27].
Recently, Montenegro et al. have reported the differential
expression of subsets of miRNAs with the progression of gestation
and inflammation in human chorioamniotic membranes [24]. Con-
sidering the fact that the placenta is a foetal organ and foetal expo-
sure to intra-amniotic infection/inflammation is systemic in nature,
we postulated that the differential expression of miRNAs confirmed
in the placenta could be shared by various foetal organs along with
systemic biological effects in the foetus. As the differential expres-
sion of miRNA-223 (miR-223) in the placenta was found according
to the presence or absence of acute chorioamnionitis in the previ-
ous study [24], the current study was conducted to determine
whether there is a differential expression of miR-223 in foetal
organs according to the presence or absence of acute chorioam-
nionitis and also whether it has potentially functional systemic con-
sequences in the foetus. Foetal or neonatal autopsy materials were
used for the analysis, and we further identified a functional target
of miR-223.
Materials and methods
Study design
Autopsy cases of foetuses and neonates met the following criteria: (i)
cases of intrauterine foetal death (IUFD) or neonatal death whose autop-
sies were performed at Seoul National University Hospital with written
informed consent for autopsy and (ii) cases whose tissue amount col-
lected and preserved during autopsy were adequate for this study. All
FFPE tissue blocks of various foetal organs from autopsy cases were
preserved. Cases with acute chorioamnionitis in the placenta were com-
pared to those without acute chorioamnionitis in the placenta and with
appropriate-for-gestational age (AGA) foetuses or neonates. Acute
chorioamnionitis was diagnosed when neutrophil infiltration was found
in the extra-placental chorioamniotic membranes or chorionic plate of
the placenta, or in the umbilical vessel walls or Wharton’s jelly, using
previously published criteria [2]. A review of the mothers’ and babies’
medical records and autopsy reports was performed for the confirma-
tion of final diagnosis of autopsy, as well as for the data collection of
the pathological results of gross specimen and microscopic examina-
tion, respectively. The collection and use of materials for research pur-
poses were approved by the Institutional Review Board of Seoul
National University Hospital, Seoul, Republic of Korea.
RNA isolation
Formalin-fixed, paraffin-embedded (FFPE) tissue blocks were cut into 5-
lm-thick slices, and paraffin was removed from FFPE tissue slices with
xylene. After washing with ethanol, tissue samples were lysed with Pro-
teinase K. Extraction of total RNA from tissue lysates was performed
with a High Pure RNA Paraffin Kit (Roche Applied Science, Indianapolis,
IN, USA). Samples were treated with DNase and Proteinase K to com-
pletely remove DNA and protein. Extracted RNA samples were stored at
80°C until analysis.
Real-time quantitative reverse transcription–
polymerase chain reaction (qRT-PCR)
Reverse transcription was conducted using the TaqMan MicroRNA Rev-
erse Transcription Kit (Applied Biosystems, Foster City, CA, USA) for
miRNA analysis and the Improm-II Reverse Transcription System (Pro-
mega, Madison, WI, USA) for mRNA analysis. All PCR analyses were
carried out using TaqMan Assays (Applied Biosystems). RPLP0
(Hs02992885_s1) was used for normalization of FoxO1 mRNA expres-
sion (Hs01054576_m1), and a custom-designed TaqMan assay for 5S
ribosomal RNA (4332078) was used for normalization of miR-223
expression (hsa-miR-223-3p, 002295) [20, 24, 28]. Reactions were car-
ried out using the 7500 Fast Real-Time PCR System (Applied Biosys-
tems). For the ribonucleoprotein immunoprecipitation (RNP-IP)
experiment, the RNA isolated from RNP-IP was reverse-transcribed to
cDNA using ReverTra Ace qPCR RT Master Mix (TOYOBO, Osaka,
Japan). The relative gene expression was determined with THUNDER-
BIRD SYBR qPCR Mix (TOYOBO), and cDNA amplified by oligo dA (15
mer) was used for normalization. The primer pairs were synthesized by
Macrogen (Seoul, Republic of Korea) as follows: FoxO1 (forward: 50-
GCCTGTAGCAACCTAAACTG-30 and reverse: 50-GGGCTTTCCACAT
GACTTGA-30) and Oligo dA (50-AAAAAAAAAAAAAAA-30). The qRT-PCR
was performed using a StepOne Plus Real-Time PCR system (Applied
Biosystems). The PCR products were resolved on 3% agarose gel,
stained with ethidium bromide, and analysed using Omega Lum G
(Aplegen Inc., Pleasanton, CA, USA).
Cell culture
Jurkat cells (human T lymphocyte cell line) were incubated in RPMI
1640 medium (Hyclone, Logan, UT, USA) supplemented with 10% heat-
inactivated foetal bovine serum (Hyclone) and a 1% solution containing
penicillin and streptomycin (Hyclone) in a humidified atmosphere of 5%
CO2 at 37°C.
Transfection of Jurkat cells with miR-223 mimic
Pre-miR-223-3p molecules (PM12301, Ambion Inc., Foster City, CA,
USA) were used to add the function of exogenous miR-223 to Jurkat
cells (human T lymphocyte cell line). For the transfection with pre-miR-
223-3p, 1 9 106 Jurkat cells were split in six-well plates, kept overnight
and transfected with pre-miR-223-3p at the concentration of 50 nM,
using siPORTTM NeoFXTM Transfection Agent (Ambion Inc.) and optiMEM
(Invitrogen, Carlsbad, CA, USA). Control cells were transfected with
miRNA precursor molecules-negative controls (scramble) (Ambion Inc.)
at equimolar concentrations. The cells were harvested 48 hrs after
transfection for the isolation of total RNA and protein. Additionally, to
assess the effects of miR-223 binding to the 30 untranslated region (30
UTR) of FoxO1 mRNA in Jurkat cells with the RNP-IP experiment, 150
pmole of pre-miR-223-3p (MC12301, Ambion Inc.) was transfected to
Jurkat cells using the Neon transfection system (Invitrogen) at
1,325 mV with three 10-ms pulses. Control cells were transfected with
mirVanaTM miRNA mimic-negative control #1 (4464058, Ambion Inc) at
equimolar concentrations. Jurkat cells (1 9 107) transfected with pre-
miR-223 or the negative control molecule were harvested after 48 hrs
for RNP-IP.
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Generation of FoxO1 30 UTR reporter construct
The FoxO1 30 UTR carrying a putative miR-223 binding site was PCR-
amplified, sequence-verified and cloned into a Spe I and Hind III site
of the pMIR-REPORTTM miRNA Expression Reporter Vector (Ambion
Inc.). PCR was carried out using an upstream primer (50-ATAATAC-
TAGTCAGATGGGTAGCAAATGGAATAGAACTTAC-30) bearing a Spe I site
and a downstream primer (50-ATAATAAGCTTTTAGATCCTTCTCAAGAA-
CACAAGAGGAAC-30) bearing a Hind III site. The 325-bp PCR product
was purified in a 1% agarose gel after electrophoresis with a Pure-
LinkTM Quick Gel Extraction Kit (Invitrogen), and its sequence was con-
firmed by DNA sequencing using an ABI 3100 sequencer (Applied
Biosystems).
Reporter gene assay
To assess miR-223 repressing the 30 UTR of FoxO1 mRNA in Jurkat
cells, 1.5 9 106 cells were transfected with 200 ng of pMIR-REPORTTM
Reporter Vector (Ambion Inc.) or 200 ng of pMIR-REPORT-FoxO1-30
UTR, 10 ng of Renilla luciferase reporter pSV40-RL (transfection con-
trol; Promega) and 50 nM of miR-223-3p precursor molecules or
equal amounts of miRNA precursor molecules-negative controls. At
48 hrs after transfection, luciferase assays were performed using the
Dual-Luciferase Reporter Assay System (Promega) according to the
manufacturer’s instructions. All experiments were carried out five
times.
Ribonucleoprotein immunoprecipitation (RNP-IP)
Transfected Jurkat cells were collected by centrifugation and then
washed twice with cold nuclease-free PBS. The cell pellet was lysed
with lysis buffer (100 mM KCl, 5 mM MgCl2, 10 mM Tris, 0.5% NP40)
supplemented with 1 mM b-mercaptoethanol, 100 U/ml Protector
RNase inhibitor (Roche), Halt protease and phosphatase inhibitor
(Thermo scientific, Rockford, IL, USA) and 25 lM MG 132 (Sigma-
Aldrich, St. Louis, MO, USA). The lysate was incubated in ice for
30 min., and the supernatant was collected by centrifugation at
15,000 9 g for 5 min. at 4°C. The supernatant was pre-cleared with
20 ll of Protein G Plus agarose beads (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA) in a rotating wheel for 30 min. at 4°C. As the
control for the comparison of extracted protein among samples, 5% of
cleared lysate was used. After pre-clearing, 1 lg of AGO2 (MABE253,
Millipore, Darmstadt, Germany) or normal rat IgG (sc-2026, Santa Cruz
Biotechnology Inc.) antibody was incubated with the pre-cleared lysate
overnight at 4°C. Twenty microlitres of Protein G Plus agarose beads
(Santa Cruz Biotechnology Inc.) was incubated with the mixture for 1 hr
at 4°C. The beads were washed four times with cold NT2 buffer supple-
mented with 1 mM b-mercaptoethanol and 20 mM EDTA. As the con-
trol for comparison of the precipitated antibody among samples, 5% of
the immunoprecipitated pellet was used. After the last washing, the
immunoprecipitated pellet was incubated in NT2 buffer supplemented
with 100 lg/ml Proteinase K (Sigma-Aldrich) for 30 min. at 55°C. For
the isolation of RNA, Isol-RNA Lysis reagent (5 prime) was added
directly to the immunoprecipitated pellet. The RNA was precipitated with
isopropanol, and the pellet was washed with 70% ethanol. The washed
pellet was then treated with DNase I (Ambion Inc.) according to manu-
facturer’s instruction.
Immunoblotting
Total proteins were isolated from Jurkat cells using RIPA buffer
(Sigma-Aldrich, St. Louis, MO, USA) containing a protease inhibitor
cocktail (Roche). Ten to twenty microlitres of protein was subjected to
10% SDS–polyacrylamide gel electrophoresis and electrotransferred
onto nitrocellulose membranes. The membranes were blocked with 5%
non-fat dry milk in Tris-buffered saline containing 0.1% v/v Tween-20
and were incubated overnight at 4°C with a rabbit polyclonal anti-FoxO1
(1:1,000; Cell Signaling, Danvers, MA, USA) and a mouse monoclonal
anti-b-actin (1:5,000; Sigma-Aldrich). A horseradish peroxidase-conju-
gated anti-rabbit or anti-mouse IgG was used as a secondary antibody.
Signals were detected by chemiluminescence using the ChemiGlow
West kit (Alpha Innotech, San Leandro, CA, USA). Densitometric analy-
ses were performed using the Multi Gauge software version 3.1 of the
imaging system LAS-4000 (Fujifilm, Tokyo, Japan). For the RNP-IP
experiment, the controls of RNP-IP were confirmed by immunoblotting
analysis probed with anti b-actin and anti-rat-IgG antibody. After prepa-
ration of controls during RNP-IP (as mentioned above), the samples
were boiled for 10 min., electrophoresed by 10% sodium dodecyl sul-
phate–polyacrylamide gel electrophoresis (SDS-PAGE), and electrotrans-
ferred onto polyvinylidene difluoride membranes (Amersham Hybomd-P;
GE Healthcare, Buckinghamshire, UK). Membranes were blocked with
1% skim milk in TBS containing 0.05% Tween-20 for 1 hr. The mem-
brane of the control for comparison of the extracted protein among the
samples was incubated with a mouse monoclonal anti-b-actin antibody
(1:5,000; ab8226, Abcam, Cambridge, UK) for 1 hr. After three washes
in TBS containing 0.05% Tween-20, the membranes were incubated
with horseradish peroxidase linked secondary antibodies (1:5,000; sc-
2005, Santa Cruz Biotechnology Inc.) for 1 hr. The membrane of the
control for comparison of the precipitated antibody among the samples
was incubated with horseradish peroxidase linked secondary antibodies
(sc-2006, Santa Cruz Biotechnology Inc.) for 1 hr. After three washes in
TBS containing 0.05% Tween-20, the chemiluminescent signals of both
membranes were detected using WesternBright Peroxide chemilumines-
cent detection reagent (Advansta, Menlo Park, CA, USA).
Immunohistochemistry
Immunohistochemistry was performed to assess FoxO1 protein expres-
sion in foetal thymus, lung and liver tissues. Five-micrometre-thick sec-
tions of FFPE blocks of foetal thymus, lung and liver tissues from
autopsy cases were placed on silanized slides. For antigen retrieval, the
sections were heated in citrate buffer (pH 6.0) for 30 min. using a
microwave. Then, endogenous peroxidases were quenched with DAKO
blocking reagent (Dako Corp., Carpinteria, CA, USA) for 15 min. The
sections were incubated with a rabbit monoclonal anti-FOXO1 antibody
(1:100, Cell Signaling) and subsequently incubated with a biotinylated
anti-immunoglobulin and streptavidin-peroxidase (DAKO LSAB kit, Dako
Corp.). Rabbit mAb IgG isotype (1:100; Cell Signaling) was used as a
negative control. Colour was developed using 3, 3-diaminobenzidine
tetrahydrochloride (DAB) for 3 min., and then, the sections were coun-
terstained with haematoxylin for 1 min.
Statistical analysis
To compare the continuous variables, Student’s t-test or Mann–Whitney
U-test for the independent variables and the paired t-test or Wilcoxon
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signed-rank test for the related variables were performed as appropriate.
For the categorical variables, Fisher’s exact test or chi-square test was
conducted as appropriate. All statistical analyses were performed using
SPSS version 19.0 (SPSS Inc., Chicago, IL, USA), and a P-value of
<0.05 was considered significant.
Results
miR-223 expression in various foetal organs
Eighteen FFPE samples from autopsy cases for thymus (N = 5 for
control versus N = 13 for acute chorioamnionitis), 26 samples for
lung (N = 10 for control versus N = 16 for acute chorioamnionitis)
and 11 samples for liver (N = 5 for control versus N = 6 for acute
chorioamnionitis) were available for the analysis of miR-223 expres-
sion. Demographic findings and clinical information in this study are
reported in Table 1. miR-223-3p expression levels in the foetal thy-
mus (2.55-fold), lung (1.93-fold) and liver (1.70-fold) were higher in
cases with acute chorioamnionitis than in those without the lesion
(P < 0.05 for each, Fig. 1).
Forkhead box O1 (FoxO1) as a putative target of
miR-223 in Jurkat T cells
As the foetal thymus showed a more prominent increase in miR-223
expression in cases with acute chorioamnionitis, we carried out a
computational search (www.targetscan.org: TargetScan release 6.2)
to determine a functionally and clinically relevant target of miR-223 in
T cells and found that FoxO1, a member of the forkhead box O (FoxO)
family of transcription factors, is among the putative targets of miR-
223. Therefore, Jurkat cells (Human T lymphocyte cell line) were used
for the experiments to identify a putative target of miR-223. Transfec-
tion of pre-miR-223-3p into Jurkat cells induced a 95.8-fold increase
in miR-223 expression (P < 0.05, Fig. 2A). While FoxO1 mRNA
expression did not differ after the transfection of pre-miR-223-3p
(P > 0.4, Fig. 2B), FoxO1 protein expression decreased by 21.4%
with pre-miR-223-3p transfection (P < 0.05, Fig. 2C) by
immunoblotting.
To confirm the binding of miR-223 to the 30 UTR of FoxO1 mRNA,
a transient transfection experiment was conducted using a luciferase
reporter plasmid with the FoxO1 30 UTR containing a putative miR-
223 binding site (Fig. 3). The sequence in the 30 UTR of FoxO1 mRNA
(Human FoxO1 NM_002015 30 UTR length: 3385) (positions 1712-
1719) was predicted to bind miR-223 and is conserved in several
species, including Pan troglodytes (chimpanzee), Macaca mulatta
(rhesus), Otolemur garnettii (bushbaby) and Tupaia belangeri (treesh-
rew). Cotransfection with a reporter plasmid containing the FoxO1 30
UTR and pre-miR-223-3p induced decreases in luciferase activity,
compared to cotransfection with a mock reporter plasmid and pre-
miR-223-3p (27.1% decrease, P < 0.01, Fig. 3B) or cotransfection
with a reporter plasmid containing the FoxO1 30 UTR and miR-223
precursor molecules-negative controls (scramble) (44.6% decrease,
P < 0.01, Fig. 3B). In addition to luciferase assay, ribonucleoprotein
immunoprecipitation (RNP-IP) followed by qRT-PCR analysis was
performed to demonstrate the physical interaction between miR-223
and FoxO1 mRNA (Fig. 4). Jurkat cells were transfected with miR-
223-3p precursor or negative control (scramble), and co-immunopre-
cipitation of cell lysates was performed using anti-argonaute 2
(AGO2) antibody. For the immunoprecipitates containing miR-223-
loaded AGO2, which is a major component of the RNA-induced
silencing complex (RISC), the direct interaction between miR-223 and
FoxO1 mRNA was analysed by qRT-PCR. As shown in Figure 4,
FoxO1 mRNA was enriched only in the AGO2 IP sample in which
miR-223 was transfected, whereas there was no significant enrich-
ment of FoxO1 mRNA in the AGO2 IP sample in which the negative
control molecule (scramble) was transfected (delta Ct value: 20.24,
Fig. 4C). Taken together, these data indicate that miR-223 directly
binds to the 30 UTR of FoxO1 mRNA and negatively regulates the pro-
tein expression of FoxO1 mRNA through interaction with miR-223-
loaded AGO2/RISC.
FoxO1 protein expression in foetal thymus
We further studied FoxO1 protein expression in the foetal thymus
through immunohistochemistry (N = 5 for control versus N = 11 for
acute chorioamnionitis, Fig. 5). When FoxO1 protein expression was
assessed using a four-tiered grading system (0, 1+, 2+, 3+), the
cases with acute chorioamnionitis showed a significantly decreased
FoxO1 immunoreactivity in the medullary thymus than did those with-
out acute chorioamnionitis did (P = 0.015).
Discussion
The principal findings of this study are the following: (i) miR-223
expression increases with acute chorioamnionitis in foetal thymus,
lung and liver; (ii) FoxO1 is a target of miR-223 in Jurkat cells; and
(iii) FoxO1 protein immunoreactivity decreases in foetal thymus with
acute chorioamnionitis.
MiRNAs are known to be new regulators of immune cell develop-
ment and function [29, 30], and miR-223 specifically has been
reported to be involved in the differentiation and maturation of granu-
locytes [31, 32]. The disruption of the physiological function of miR-
223 in granulocyte differentiation is associated with the development
of acute leukaemia [33, 34]. Because of its role in the regulation of
the immune response, miR-223 also has been proposed to be a
potential prognostic and therapeutic target for the inflammatory dis-
orders [35]. In the current study, foetal thymus, lung and liver tissues
were selected to determine the differential expression of miR-223 in
the context of acute chorioamnionitis, as those foetal organs are
known to be associated with foetal immunity and inflammation. It is
also well-known that foetal thymus, liver and bone marrow are central
to the development of the foetal immune system [36, 37]. A large
body of evidence indicates that acute placental inflammation is asso-
ciated with inflammation in the foetal lung and is ultimately associated
with foetal lung maturity [38–40]. The expression pattern of miR-223
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Table 1 Demographics of study population
Characteristics
Acute chorioamnionitis
No (N = 5) Yes (N = 13)†
Thymus
Maternal age (yr)* 29 (25–42) 32 (25–43) 0.458
Nulliparity (%) 40.0 25.0 0.600
Gestational age at delivery (week)* 21.3 (19.3–24.0) 22.7 (18.0–26.7) 0.554
Birthweight (g)* 370 (185–690) 560 (120–820) 0.343
Foetal gender (male, %) 100.0 54.5 0.231
Indication of autopsy >0.999
Spontaneous abortion/preterm delivery (%) 80.0 76.9
Cervical insufficiency (incompetence os of cervix) 20.0 23.1
Preterm premature rupture of membranes 20.0 30.8
Preterm labour 40.0 23.1
Induced/Therapeutic abortion/preterm delivery (%) 20.0 23.1
Oligohydramnios 20.0 0.0
Placental abruption 0.0 7.7
Therapeutic abortion 0.0 7.7
Major structural abnormalities 0.0 7.7
Characteristics
Acute chorioamnionitis
No (N = 5) Yes (N = 6)
Liver
Maternal age (yr)* 36 (29–42) 32 (29–43) 0.313
Nulliparity (%) 40.0 0.0 0.182
Gestational age at delivery (week)* 21.3 (18.0–24.0) 23.5 (21.4–28.3) 0.082
Birthweight (g)* 370 (130–690) 585 (120–820) 0.361
Foetal gender (male, %) 80.0 60.0 >0.999
Indication of autopsy 0.455
Spontaneous abortion/preterm delivery (%) 100.0 66.7
Cervical insufficiency (Incompetence os of cervix) 20.0 16.7
Preterm premature rupture of membranes 40.0 50.0
Preterm labour 40.0 0.0
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in these foetal organs indicates that the biologic responses of the foe-
tus to intra-amniotic bacterial infection occur in multiple foetal
organs, and this is consistent with the findings of previous studies
that chorioamnionitis may lead to multi-organ foetal diseases affect-
ing the brain, lung, intestines and thymus [2, 41–47].
The observations in the present study provide the biological evi-
dence that miR-223 regulates FoxO1. FoxO1 is a member of the
forkhead box O (FoxO) family of transcription factors that includes
FoxO1, FoxO3, FoxO4 and FoxO6 [48]. FoxO1 plays an important
role in the regulation of gluconeogenesis and glycogenolysis as well
as a central role in the regulation of adipogenesis [49, 50]. The FoxO
transcription factor family also carries out significant roles in
immune cell homeostasis and the regulation of inflammation in T
cells, B cells and neutrophils [51, 52]. These functions are strictly
modulated by the ability of FoxO proteins to interact with various
transcription factors in response to multiple external stimuli [53].
When we performed a computational search (www.targetscan.org)
to determine a functionally and clinically relevant target of miR-223
Table 1. Continued
Characteristics
Acute chorioamnionitis
No (N = 5) Yes (N = 6)
Induced/Therapeutic abortion/preterm delivery (%) 0.0 33.3
Oligohydramnios 0.0 0.0
Placental abruption 0.0 16.7
Therapeutic abortion 0.0 0.0
Major structural abnormalities 0.0 16.7
Characteristics
Acute chorioamnionitis
No (N = 10) Yes (N = 16)
Lung
Maternal age (yr)* 29 (21–42) 32 (25–43) 0.510
Nulliparity (%) 44.4 28.6 0.657
Gestational age at delivery (week)* 20.5 (16.0–24.0) 22.4 (16.0–24.7) 0.356
Birthweight (g)* 350 (130–690) 530 (120–820) 0.233
Foetal gender (male, %) 70.0 46.7 0.414
Indication of autopsy 0.340
Spontaneous abortion/preterm delivery (%) 70.0 87.5
Cervical insufficiency (Incompetence os of cervix) 30.0 18.8
Preterm premature rupture of membranes 20.0 50.0
Preterm labour 20.0 18.8
Induced/Therapeutic abortion/preterm delivery (%) 30.0 12.5
Oligohydramnios 10.0 0.0
Placental abruption 0.0 6.8
Therapeutic abortion 10.0 0.0
Major structural abnormalities 10.0 6.8
*Median (range).
†Two cases were excluded in the immunohistochemical analysis of FoxO1 protein expression in foetal thymus.
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in the context of acute chorioamnionitis, FoxO1 was among the
putative targets of miR-223.
The activity of FoxO transcription factors is known to be regulated
by post-translational modifications, such as phosphorylation, acetyla-
tion and ubiquitination [54]. Recently, miRNA-mediated post-transcrip-
tional modification has been reported as one of the regulation
mechanisms that affect the activity of FoxO transcription factors. For
example, miR-182 [55], miR-155 [56] and miR-96 [57] have an impact
on various cellular functions by targeting FoxO3. In terms of FoxO1,
Guttila and colleagues have demonstrated the regulation of FoxO1 by
miR-27a, miR-96 and miR-182 in breast cancer cells [58], and Has-
seine et al. have studied the impact of miR-139 on FoxO1 action by
decreasing FoxO1 protein in mouse hepatocytes [59]. Furthermore,
Wu and colleagues have reported FoxO1 as the putative target of miR-
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Fig. 1miR-223 expression in foetal
organs. miR-223-3p expression levels in
the foetal thymus (2.55-fold), lung (1.93-
fold) and liver (1.70-fold) were higher in
cases with acute chorioamnionitis than in
those without the lesion (P < 0.05 for
each). ACA, acute chorioamnionitis. Rela-
tive expressions are presented as columns
(median) and error bars (interquartile
range).
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Fig. 2 Promotion of FoxO1 mRNA by miR-
223 in Jurkat cells. (A) Transfection of
pre-miR-223-3p into Jurkat cells induced
a 95.8-fold increase in miR-223-3p
expression (P < 0.05). (B) FoxO1 mRNA
expression did not differ after the trans-
fection of pre-miR-223-3p (P > 0.4). (C)
FoxO1 protein expression decreased by
21.4% with pre-miR-223-3p transfection
(P < 0.05) by immunoblotting. FoxO1:
Forkhead box O1. Relative expressions are
presented as mean  S.E.M.
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223 in colorectal cancer cells, cervical cancer cells and hepatoma cells
[60]. miRNAs regulate target genes through mRNA degradation/insta-
bility or the inhibition of translation of mRNAs [61,62]. The observa-
tions in the current study showed that miR-223 regulates FoxO1 by
decreasing FoxO1 at the protein level, but not at the mRNA level. This
indicates that FoxO1 mRNA is silenced by miR-223 mainly by transla-
tional repression, but not by FoxO1 mRNA decay.
The thymus is histologically divided into the cortex and medulla.
The central cortex is the site of the early events in thymocyte devel-
opment [63]. The peripheral medulla, where the late events in thy-
mocyte development take place, shows less dense cellularity but
contains more mature T cells than the cortex does [63]. The differ-
ential expression of FoxO1 protein according to the presence or
absence of acute chorioamnionitis in the thymic medulla, but not in
the thymic cortex, is intriguing. Based on the difference in the differ-
ential expression of FoxO1 between the two parts of the thymus, the
possibility exists that miR-223 and FoxO1 could affect the later
0.0
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2.5
P < 0.01 P < 0.01
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Fig. 3miR-223 binding to the 30 UTR of FoxO1 mRNA in luciferase
assay. (A) The sequence in the 30 UTR of FoxO1 mRNA (Human FoxO1
NM_002015 30UTR, length: 3385) (positions 1712–1719) was predicted
to bind miR-223 and is conserved in several species (Ptr, Pan troglo-
dytes; Mml, Macaca mulatta; Oga, Otolemur garnettii; Tbe, Tupaia
belangeri). (B) Cotransfection with a reporter plasmid containing FoxO1
30 UTR and pre-miR-223-3p induced decreases in the luciferase activity
compared to cotransfection with a mock reporter plasmid and pre-miR-
223-3p (27.1% decrease, P < 0.01) or cotransfection with a reporter
plasmid containing FoxO1 30 UTR and miR-223 precursor molecules-
negative controls (scramble) (44.6% decrease, P < 0.01). FoxO1: Fork-
head box O1, NS: not significant. Relative Firefly/Renilla ratios are pre-
sented as mean  S.E.M.
β-actin
ΔC
т
0
5
10
15
20
25
cDNA
FoxO1
Scramble Pre-miR-223
IgG (light chain)
IgG α-AGO2 α-AGO2IgG
α-AGO2 α-AGO2
Scramble Pre-miR-223
IgG IgG
α-AGO2 α-AGO2IgG IgG
Scramble Pre-miR-223
Cell lysate 
After immunoprecipitation
qRT-PCR
UD UD UD
UD: Undetermined
IgG (heavy chain)
A
B
C
Fig. 4miR-223 binding to the 30 UTR of FoxO1 mRNA in ribonucleopro-
tein immunoprecipitation (RNP-IP). (A) The expressions of b-actin in
the cell lysate were similar, irrespective of cotransfection with pre-miR-
223-3p (versus negative control: scramble) and anti-argonaute 2
(AGO2) antibody (versus normal rat IgG antibody). (B) The amounts of
heavy-chain and light-chain IgG in the beads after immunoprecipitation
were similar, irrespective of cotransfection with pre-miR-223-3p (versus
negative control: scramble) and anti-AGO2 antibody (versus normal rat
IgG antibody). (C) FoxO1 mRNA was enriched only in the immunopre-
cipitates containing miR-223-loaded AGO2, whereas FoxO1 mRNA was
not significantly enriched in the AGO2 IP sample in which the negative
control molecule was transfected. AGO, argonaute-2, UD, undetermined,
FoxO1, Forkhead box O1.
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stages of T-cell development. A recent study on the changes in foe-
tal thymus according to intrauterine inflammation reported a differ-
ence in terms of the foetal thymic immune cell populations of the
cortex and medulla: the medulla was found to have a greater CD4:
CD8 ratio than the cortex [64].
Several studies have investigated thymic changes in the context of
chorioamnionitis. The association between foetal thymic involution and
foetal inflammatory response syndrome has been previously reported
[65, 66]. Thymic changes after intrauterine inflammation, such as the
decrease in thymus-to-body weight ratios [43] and alterations in foetal
thymic immune cell populations [64], have also been reported. ‘Devel-
opmental programming’ during foetal or infantile periods is known to
be closely associated with adult health problems, including coronary
heart disease, stroke, hypertension and diabetes [67, 68]. Thus, the
long-term consequences in the adaptive immune system and other
organs by the alteration of miR-223 and FoxO1 expression in the pres-
ence of placental inflammation need to be further clarified by additional
observational and mechanistic studies. However, the findings in this
study suggest that foetal programming by an abnormal intrauterine
environment has potentially long-term and systemic effects, as the
alteration of miR-223 occurs simultaneously in multiple organs and in
the same direction. In addition, FoxO1 is a known regulator of gluco-
neogenesis, glycogenolysis and adipogenesis [49], as well as a modu-
lator of the immune system and inflammation [50].
In summary, foetuses with inflammation in the chorioamniotic
membranes showed increased expression of miR-223 in the thymus,
x400 x400
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chorioamnionitis
Thymic medulla of a case with acute  
chorioamnionitis
x100
FoxO1
x100
x400 x400
FoxO1
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Fig. 5 FoxO1 protein expression in foetal
thymus. Immunohistochemistry images
from a representative case show that
cases with acute chorioamnionitis had
lower FoxO1 protein expression in the thy-
mic medulla than those without acute
chorioamnionitis. Non-specific binding
was not observed in the IgG isotype con-
trols (bottom). FoxO1, Forkhead box O1.
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lung and liver, and FoxO1 is a target of miR-223. These findings sug-
gest that the post-transcriptional regulation of genes by miR-223 is a
novel component of the foetal systemic inflammatory response to
intrauterine infection and inflammation.
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